IM Cannabis (IMCC) Stock Price, Quote, News & History

IM Cannabis Corp (IMCC) Stock Price, Quote, News & History

IMCCNASDAQ

Trade with Public

$0.8300

-0.12-12.63%

At close: Feb 23, 4:00 PM EST

$0.8881

0.05817.00%

After Hours: 4:23 PM EST

Key Statistics

Open

$0.96

$0.83

Volume / Avg.

49.71K / 154.42K

Day Range

$0.81 - $0.96

52 Wk Range

0.81 - 7.12

Market Cap

$5.24M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.66%

Days to Cover

Recent IM Cannabis Corp News

White House Considers Cannabis Reclassification, Stops Short Of Legalization: Stocks To Watch

Trump is expected to sign an executive order reclassifying cannabis to Schedule III, easing federal restrictions.

Vandana Singh

This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

This week in cannabis: major mergers, innovative launches, key regulatory updates & leadership changes drive industry transformation.

Javier Hasse

IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3

International medical cannabis company IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial results for the third quarter ended Sept. 30, 2024. The company reported revenue from Germany grew 66% year-over-year, reaching CA$5.8 million ($4.1 million). "While the 66% growth we delivered in Germany, to reach $5.8M this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025," Oren Shuster, the company's CEO, said. "Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis we will use to deliver in 2025."

Jelena Martinovic

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

2.54M

Investing Cash Flow (TTM)

-53.00K

Financing Cash Flow (TTM)

355.00K

Free Cash Flow (TTM)

2.44M

Capital Expenditure (TTM)

-108.00K

Net Change in Cash (TTM)

2.85M

Valuation Metrics

Enterprise Value

$16.51M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

0.07

PB Ratio (TTM)

2.16

Earnings Yield % (TTM)

-52.58%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

5.68

Price / EBITDA (TTM)

0.94

Price / Free Cash Flow (TTM)

1.53

Book Value / Share

$0.44

Company Debt

Total Debt

$15.19M

LT Debt

$1.30M

LT Debt Issuance (TTM)

$2.41M

LT Debt Repayment (TTM)

-$2.06M

Total Cash

$794.00K

Debt to Equity

4.44

Issuance of Debt (TTM)

$351.00K

Repayment of Debt (TTM)

-$2.06M

Key Statistics

Open

$0.96

$0.83

Volume / Avg.

49.71K / 154.42K

Day Range

$0.81 - $0.96

52 Wk Range

0.81 - 7.12

Market Cap

$5.24M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.66%

Days to Cover

About

Sector

Health Care

Industry

Pharmaceuticals

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy IM Cannabis (IMCC) stock?

You can purchase shares of IM Cannabis (NASDAQ:IMCC) through any online brokerage.

View our list of the best stock brokerages

Who are IM Cannabis (IMCC) competitors?

Other companies in IM Cannabis’s space includes: Iterum Therapeutics PLC (NASDAQ:ITRM), Gelteq Ltd (NASDAQ:GELS), 60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP), Addex Therapeutics Ltd (NASDAQ:ADXN) and Kiora Pharmaceuticals Inc (NASDAQ:KPRX).

What is the forecast, or price target, for IM Cannabis (IMCC) stock?

There is no analysis for IM Cannabis to provide a consensus price target.

What is the current price for IM Cannabis (IMCC)?

The stock price for IM Cannabis (NASDAQ: IMCC) is $0.8881 last updated February 23, 2026 at 4:23 PM EST.

Does IM Cannabis (IMCC) pay a dividend?

There are no upcoming dividends for IM Cannabis.

When is IM Cannabis (NASDAQ:IMCC) reporting earnings?

IM Cannabis does not have any upcoming earnings scheduled.

Is IM Cannabis (IMCC) going to split?

There is no upcoming split for IM Cannabis.

What sector and industry does IM Cannabis (IMCC) operate in?

IM Cannabis is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Iterum Therapeutics PLC

60 Degrees Pharmaceuticals Inc

NASDAQ:SXTP

$3.05

4.26%

Addex Therapeutics Ltd

NASDAQ:ADXN

$7.33

1.09%

Kiora Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

NASDAQ:SNOA

$2.74

-3.65%

Redhill Biopharma Ltd

NASDAQ:RDHL

$0.97

1.04%

Key Statistics

Open

$0.96

$0.83

Volume / Avg.

49.71K / 154.42K

Day Range

$0.81 - $0.96

52 Wk Range

0.81 - 7.12

Market Cap

$5.24M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.66%

Days to Cover

Recent IM Cannabis Corp News

White House Considers Cannabis Reclassification, Stops Short Of Legalization: Stocks To Watch

Trump is expected to sign an executive order reclassifying cannabis to Schedule III, easing federal restrictions.

Vandana Singh

This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

This week in cannabis: major mergers, innovative launches, key regulatory updates & leadership changes drive industry transformation.

Javier Hasse

IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3

Jelena Martinovic

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

2.54M

Investing Cash Flow (TTM)

-53.00K

Financing Cash Flow (TTM)

355.00K

Free Cash Flow (TTM)

2.44M

Capital Expenditure (TTM)

-108.00K

Net Change in Cash (TTM)

2.85M

Valuation Metrics

Enterprise Value

$16.51M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

0.07

PB Ratio (TTM)

2.16

Earnings Yield % (TTM)

-52.58%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

5.68

Price / EBITDA (TTM)

0.94

Price / Free Cash Flow (TTM)

1.53

Book Value / Share

$0.44

Company Debt

Total Debt

$15.19M

LT Debt

$1.30M

LT Debt Issuance (TTM)

$2.41M

LT Debt Repayment (TTM)

-$2.06M

Total Cash

$794.00K

Debt to Equity

4.44

Issuance of Debt (TTM)

$351.00K

Repayment of Debt (TTM)

-$2.06M

Key Statistics

Open

$0.96

$0.83

Volume / Avg.

49.71K / 154.42K

Day Range

$0.81 - $0.96

52 Wk Range

0.81 - 7.12

Market Cap

$5.24M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.66%

Days to Cover

About

Sector

Health Care

Industry

Pharmaceuticals

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry